◀ Back to GP6

GP6 — MAPK10

Text-mined interactions from Literome

Dobreva et al., Immunopharmacol Immunotoxicol 2007 : The immunomodulatory activity of C3 binding glycoprotein ( C3bgp ) is mediated by the complement receptor type III and mitogen activated protein kinase signal transduction pathways
Oh et al., Naunyn Schmiedebergs Arch Pharmacol 2009 : Our results revealed that the CTB glycoprotein in the presence of DEHP inhibits the translocation of PKC from cytosol to membrane and the phosphorylation of p44/42 MAPK in primary cultured T lymphocytes
Pierangeli et al., Lupus 2010 (Antiphospholipid Syndrome...) : This review article will address the experimental and/or clinical evidence behind some of these potential ` immunomodulatory ' approaches ( tissue factor inhibition, P38 mitogen activated protein kinase inhibition , nuclear factor-kappaB inhibition, platelet glycoprotein receptor inhibition, hydroxychloroquine, statins, inhibition of beta(2)GPI and/or anti-beta(2)GPI binding to target cells, complement inhibition, and B cell inhibition ) in antiphospholipid syndrome
Oh et al., Cell Biochem Funct 2010 : Our results showed that the CTB glycoprotein in the presence of DEHP inhibits the production of intracellular ROS, the phosphorylation of ERK1/2, and p38 MAPK in HMC-1 cells
Lee et al., Naunyn Schmiedebergs Arch Pharmacol 2012 : With regard to proliferation related signals, our finding indicated that SJSZ glycoprotein ( 50 µg/ml ) diminished the production of intracellular ROS, activity of phosphorylated ERK, p38 MAPK , NF-?B ( p50 and p65 ), PCNA, and cyclin D1/CDK4 in MNNG induced BNL CL.2 cells